Evogene Ltd. - Ordinary Shares (EVGN): Price and Financial Metrics


Evogene Ltd. - Ordinary Shares (EVGN): $2.82

-0.10 (-3.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVGN to Watchlist
Sign Up

Industry: Agriculture


Ranked

of 32

in industry

EVGN POWR Grades


  • EVGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 86.12% of US stocks.
  • The strongest trend for EVGN is in Growth, which has been heading down over the past 48 weeks.
  • EVGN ranks lowest in Growth; there it ranks in the 3rd percentile.

EVGN Stock Summary

  • With a price/sales ratio of 99.95, Evogene Ltd has a higher such ratio than 96.74% of stocks in our set.
  • Revenue growth over the past 12 months for Evogene Ltd comes in at -84.1%, a number that bests merely 1.81% of the US stocks we're tracking.
  • The volatility of Evogene Ltd's share price is greater than that of 95.05% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to EVGN, based on their financial statements, market capitalization, and price volatility, are TBPH, OTIC, APTX, AGIO, and BLUE.
  • Visit EVGN's SEC page to see the company's official filings. To visit the company's web site, go to www.evogene.com.

EVGN Valuation Summary

  • In comparison to the median Healthcare stock, EVGN's EV/EBIT ratio is 108.87% lower, now standing at -2.6.
  • Over the past 106 months, EVGN's price/sales ratio has gone up 89.4.
  • EVGN's price/sales ratio has moved up 89.4 over the prior 106 months.

Below are key valuation metrics over time for EVGN.

Stock Date P/S P/B P/E EV/EBIT
EVGN 2021-08-31 102.7 1.5 -4.3 -2.6
EVGN 2021-08-30 89.6 1.3 -3.7 -2.0
EVGN 2021-08-27 94.4 1.4 -3.9 -2.2
EVGN 2021-08-26 92.0 1.4 -3.8 -2.1
EVGN 2021-08-25 95.8 1.4 -4.0 -2.3
EVGN 2021-08-24 92.3 1.4 -3.8 -2.2

EVGN Growth Metrics

  • Its 2 year revenue growth rate is now at -40.47%.
  • Its 5 year revenue growth rate is now at -90.66%.
  • Its 3 year cash and equivalents growth rate is now at 958.42%.
EVGN's revenue has moved down $707,000 over the prior 24 months.

The table below shows EVGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 1.04 -19.514 -23.374
2019-12-31 0.753 -17.666 -18.112
2018-12-31 1.747 -15.161 -20.758
2017-12-31 3.381 -15.929 -20.838
2016-12-31 6.54 -11.693 -19.592
2015-12-31 11.129 -12.407 -17.213

EVGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EVGN has a Quality Grade of D, ranking ahead of 9.77% of graded US stocks.
  • EVGN's asset turnover comes in at 0.015 -- ranking 86th of 90 Chemicals stocks.
  • 500 - Internal server error

The table below shows EVGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.015 0.448 -2.136
2019-12-31 0.012 0.556 -0.546
2018-12-31 0.026 0.169 -0.317
2017-12-31 0.039 0.159 -0.253
2016-12-31 0.063 0.138 -0.203
2015-12-31 0.093 0.258 -0.146

EVGN Price Target

For more insight on analysts targets of EVGN, see our EVGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

EVGN Stock Price Chart Interactive Chart >

Price chart for EVGN

EVGN Price/Volume Stats

Current price $2.82 52-week high $10.24
Prev. close $2.92 52-week low $2.38
Day low $2.78 Volume 248,400
Day high $2.90 Avg. volume 867,725
50-day MA $2.89 Dividend yield N/A
200-day MA $4.35 Market Cap 72.62M

Evogene Ltd. - Ordinary Shares (EVGN) Company Bio


Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company was founded in 1999 and is based in Rehovot, Israel.


EVGN Latest News Stream


Event/Time News Detail
Loading, please wait...

EVGN Latest Social Stream


Loading social stream, please wait...

View Full EVGN Social Stream

Latest EVGN News From Around the Web

Below are the latest news stories about Evogene Ltd that investors may wish to consider to help them evaluate EVGN as an investment opportunity.

Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments, announced today that Mr. Ofer Haviv, Evogene's President and CEO, will be interviewed in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021. Mr. Haviv's interview will focus on Evogene's disruptive technologies; its tailor-made engines for product discovery and

Yahoo | September 14, 2021

What Makes Evogene (EVGN) a New Buy Stock

Evogene (EVGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | September 3, 2021

Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, taking place from September 9-15, 2021. Mr. Haviv's presentation will focus on Evogene's disruptive technologies, its tailor-made engines for product discovery and development and its

Yahoo | September 1, 2021

Canonic Announces Pre-Launch of Medical Cannabis Products in Israel

Canonic Ltd , a company focused on the development of medical cannabis products and a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN ) (TASE: EVGN), announced today the pre-launch of its first-generation medical cannabis inflorescence products , reported PRNewswire . Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN) developing medical Cannabis products through a Computational Predictive Biology (CPB) platform, aimed at improving active compounds yield, genetic Full story available on Benzinga.com

Benzinga | August 31, 2021

Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel

Canonic Ltd, a company focused on the development of medical cannabis products and a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the pre-launch of its first-generation medical cannabis inflorescence products.

Yahoo | August 31, 2021

Read More 'EVGN' Stories Here

EVGN Price Returns

1-mo 0.71%
3-mo -21.67%
6-mo -36.63%
1-year -8.74%
3-year -9.03%
5-year N/A
YTD -40.00%
2020 209.21%
2019 -23.23%
2018 -35.50%
2017 -39.80%
2016 -36.65%

Continue Researching EVGN

Want to see what other sources are saying about Evogene Ltd's financials and stock price? Try the links below:

Evogene Ltd (EVGN) Stock Price | Nasdaq
Evogene Ltd (EVGN) Stock Quote, History and News - Yahoo Finance
Evogene Ltd (EVGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0596 seconds.